MHRA approves Siiltibcy as a diagnostic aid for Mycobacterium tuberculosis infection, including disease

An Expert Working Group has completed a review into how the potential risks associated with antidepressant medicines are communicated to patients

Zambon SpA is recalling an affected batch as a precautionary measure due to out of specification results for unknown impurities during ongoing stability testing.

The MHRA is inviting the next generation of doctors to explore how genetics could improve prescribing and patient safety in the UK.

Examples of what manufacturers must report to the MHRA under the medical device vigilance system when incidents involving their devices occur in the UK.

Updated product information for healthcare professionals and patients regarding the small risk of severe acute pancreatitis in patients taking GLP-1s.

As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants.